Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack
NCT ID: NCT02089074
Last Updated: 2017-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
265 participants
INTERVENTIONAL
2012-11-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention Medication
NCT01684176
An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia
NCT01504672
A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction
NCT03621111
The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life and Investigate What This Means to You
NCT03079375
A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
NCT07159399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
drug use counselling
Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
Drug use counselling
Control group
The patients in the control group receive no intervention just treatment and follow up according to national standards
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug use counselling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Residing in Central Norway
* Examined within 2 weeks after the onset of symptoms
* Modified Rankin Scale 3 or less and living at home
* enrolled in the MIDNOR-TIA study NCT02038725
* Informed consent
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Olavs Hospital
OTHER
Helse Midt-Norge
OTHER
Sykehusapotekene i Midt Norge
UNKNOWN
Norwegian University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bent Indredavik, PhD, Prof
Role: STUDY_DIRECTOR
Norwegian University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ålesund Sykehus
Ålesund, , Norway
Kristiansund Sykehus
Kristiansund, , Norway
Levanger Sykehus
Levanger, , Norway
Molde Sykehus
Molde, , Norway
Namsos Sykehus
Namsos, , Norway
St Olavs Hospital
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012/1224a
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.